Vascular Dementia - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Vascular Dementia Key assessments Patient Segmentation in Vascular Dementia Vascular Dementia Risk & Burden Factors driving growth in a specific Vascular Dementia patient population
January 2022
60 pages
Vascular Dementia - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Dementia Pipeline Analysis Vascular Dementia Market Size and Trends Vascular Dementia Market Opportunities Impact of upcoming Therapies in Vascular Dementia Vascular Dementia Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition ...
January 2022
200 pages
Vulvovaginal Candidiasis - Epidemiology Forecast to 2032
US$ 3,950.00
... with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Vulvovaginal Candidiasis Key assessments Patient Segmentation in Vulvovaginal Candidiasis Vulvovaginal Candidiasis Risk & Burden Factors driving growth in a specific Vulvovaginal Candidiasis patient population
January 2022
60 pages
Vulvovaginal Candidiasis - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Vulvovaginal Candidiasis Report Assessment Current Treatment Practices in Vulvovaginal Candidiasis Unmet Needs in Vulvovaginal Candidiasis Market Attractiveness Market Drivers and Barriers KEY BENEFITS ...
January 2022
200 pages
Wet Macular Degeneration - Epidemiology Forecast to 2032
US$ 3,950.00
... with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Wet Macular Degeneration Key assessments Patient Segmentation in Wet Macular Degeneration Wet Macular Degeneration Risk & Burden Factors driving growth in a specific Wet Macular Degeneration patient population
January 2022
60 pages
Wet Macular Degeneration - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Wet Macular Degeneration Report Assessment Current Treatment Practices in Wet Macular Degeneration Unmet Needs in Wet Macular Degeneration Market Attractiveness Market Drivers and Barriers KEY BENEFITS ...
January 2022
200 pages
Wilson Disease - Epidemiology Forecast to 2032
US$ 3,950.00
... 7MM with respect to the patient population Key strengths 10 Year Forecast 7MM Coverage Total Cases in Wilson Disease Key assessments Patient Segmentation in Wilson Disease Wilson Disease Risk & Burden Factors driving growth in a specific Wilson Disease patient population
January 2022
60 pages
Wilson Disease - Market Insight, Epidemiology and Market Forecast -2032
US$ 7,500.00
... Wilson Disease Pipeline Analysis Wilson Disease Market Size and Trends Wilson Disease Market Opportunities Impact of upcoming Therapies in Wilson Disease Wilson Disease Report Key Strengths 10 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Wilson ...
January 2022
200 pages
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “1,3-Beta-Glucan Synthase Inhibitor The report ...
January 2022
60 pages
11 Beta-Hydroxysteroid Dehydrogenase (11ЯHSD) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “11 Beta-Hydroxysteroid Dehydrogenase (11ßHSD) Inhibitor The ...
January 2022
60 pages
11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ЯHSD1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor ...
January 2022
60 pages
20s Proteasome Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “20s Proteasome Inhibitor The report assesses ...
January 2022
90 pages
30S Ribosomal Subunit (30S RNA) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “30S Ribosomal Subunit (30S RNA) Inhibitor The report ...
January 2022
120 pages
4-1BB receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “4-1BB receptor Agonist The report assesses ...
January 2022
60 pages
50S Ribosomal Subunit (50S RNA) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “50S Ribosomal Subunit (50S RNA) Inhibitor The report ...
January 2022
90 pages
5-Alpha Reductase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-Alpha Reductase Inhibitor The report assesses ...
January 2022
60 pages
5-HT1 Agonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT1 Agonist The report assesses the active 5-HT1 Agonist pipeline ...
January 2022
120 pages
5-HT1 Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT1 Antagonist The report assesses the active 5-HT1 Antagonist ...
January 2022
90 pages
5-HT1A Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT1A Antagonist The report assesses the active 5-HT1A Antagonist ...
January 2022
60 pages
5-HT1B Agonist - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT1B Agonist The report assesses the active 5-HT1B Agonist ...
January 2022
90 pages
5-HT1B Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT1B Antagonist The report assesses the active 5-HT1B Antagonist ...
January 2022
60 pages
5-HT1D Agonist - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT1D Agonist The report assesses the active 5-HT1D Agonist ...
January 2022
90 pages
5-HT2 Agonist - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT2 Agonist The report assesses the active 5-HT2 Agonist pipeline ...
January 2022
90 pages
5-HT2 Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT2 Antagonist The report assesses the active 5-HT2 Antagonist ...
January 2022
120 pages
5-HT2A Agonists - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT2A Agonist The report assesses the active 5-HT2A Agonist ...
January 2022
60 pages
5-HT2B Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT2B Antagonist The report assesses the active 5-HT2B Antagonist ...
January 2022
60 pages
5-HT2C Agonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT2C Agonist The report assesses the active 5-HT2C Agonist ...
January 2022
60 pages
5-HT2C Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT2C Antagonist The report assesses the active 5-HT2C Antagonist ...
January 2022
90 pages
5-HT4 Agonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT4 Agonist The report assesses the active 5-HT4 Agonist pipeline ...
January 2022
120 pages
5-HT4 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT4 Antagonist The report assesses the active 5-HT4 Antagonist ...
January 2022
60 pages
5-HT4 Partial Agonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT4 Partial Agonist The report assesses the active 5-HT4 Partial ...
January 2022
60 pages
5-HT6 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT6 Antagonist The report assesses the active 5-HT6 Antagonist ...
January 2022
60 pages
5-HT7 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “5-HT7 Antagonist The report assesses the active 5-HT7 Antagonist ...
January 2022
60 pages
Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Acetylcholine Receptor (AChR) Antagonist The report ...
January 2022
80 pages
Adenosine A1 Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A1 Receptor Agonist The report assesses ...
January 2022
60 pages
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A1 Receptor Antagonist The report ...
January 2022
60 pages
Adenosine A2 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A2 Receptor Antagonist The report ...
January 2022
60 pages
Adenosine A2A Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A2A Receptor Agonist The report assesses ...
January 2022
60 pages
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A2A Receptor Antagonist The report ...
January 2022
60 pages
Adenosine A2B Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A2B Receptor Antagonist The report ...
January 2022
60 pages
Adenosine A3 Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A3 Receptor Agonist The report assesses ...
January 2022
60 pages
Adenosine A3 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine A3 Receptor Antagonist The report ...
January 2022
60 pages
Adenosine Antagonists - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adenosine Antagonist The report assesses ...
January 2022
90 pages
Adrenergic Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adrenergic Antagonist The report assesses ...
January 2022
120 pages
Adrenergic uptake inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Adrenergic Uptake Inhibitor The report assesses ...
January 2022
60 pages
Akt1 Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Akt1 Inhibitor The report assesses the active Akt1 Inhibitor ...
January 2022
120 pages
Aldose Reductase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Aldose Reductase Inhibitor The report assesses ...
January 2022
60 pages
